Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2578

Sort by

Sort Order Select

Journal Articles

Retinoic acid–responsive CD8 effector T cells are selectively increased in IL-23–rich tissue in gastrointestinal GVHD

Jennifer A. Ball, Andrew Clear, James Aries, Sarah Charrot, Caroline Besley, Matt Mee, Andrew Stagg, James O. Lindsay, Jamie Cavenagh, Maria Calaminci, John G. Gribben, Jeff Davies

Blood (2021) 137 (5): 702–717.

https://doi.org/10.1182/blood.2020005170

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Blood (2019) 134 (24): 2159–2170.

https://doi.org/10.1182/blood.2019000779

Published: 2019

Includes: Supplemental data

Journal Articles

Effect of Extended Platelet Storage on Platelet Metabolism and Clot Retraction

Prajeeda M Nair, PhD, Michael Adam Meledeo, PhD, Xiaowu Wu, MD MSc, Grantham Peltier, MS, Bin Liu, BS, Kristin M Reddoch-Cardenas, PhD, James Bynum, PhD, Andrew P. Cap, MD PhD

Blood (2019) 134 (Supplement_1): 2450.

https://doi.org/10.1182/blood-2019-131116

Published: 2019

Journal Articles

Altered Megakaryocytes Are Associated with Development of Pulmonary Fibrosis in Mice Carrying the Hypomorphic Gata1 low Mutation

Barbara Bacci, PhD, Francesca Gobbo, Mariana Roccaro, Angelo Peli, PhD, Maria Zingariello, PhD, Fabrizio Martelli, PhD, Paola Verachi, Claudio Bardelli, PhD, Maria Mazzarini, Giuseppe Sarli, PhD, Anna Rita Migliaccio, PhD

Blood (2019) 134 (Supplement_1): 2336.

https://doi.org/10.1182/blood-2019-123994

Published: 2019

Journal Articles

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Fernanda Marconi Roversi, Maura Lima Pereira Bueno, undergraduate, Cristiane Okuda Torello, PhD, Fernanda I Della Via, MSc, Renata Giardini Rosa, PhD, Juares Ednaldo Romero Bianco, PhD, Adriana Silva Santos Duarte, PhD, Eduardo M Rego, MD PhD, Alessio Molinari, Maurizio Botta, Sara T Olalla Saad, PhD

Blood (2019) 134 (Supplement_1): 4650.

https://doi.org/10.1182/blood-2019-128959

Published: 2019

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor

Lei Xiao, PhD

Blood (2019) 134 (Supplement_1): 4631.

https://doi.org/10.1182/blood-2019-130703

Published: 2019

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Michael Leukam, MDMS, James Godfrey, MD, Sravya Tumuluru, Girish Venkataraman, MD MBBS, Sonali M. Smith, MD, Riyue Bao, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 924.

https://doi.org/10.1182/blood-2019-131562

Published: 2019

Journal Articles

Euroclonality-NGS DNA Capture Panel for Integrated Analysis of IG/TR Rearrangements, Translocations, Copy Number and Sequence Variation in Lymphoproliferative Disorders

Blood (2019) 134 (Supplement_1): 888.

https://doi.org/10.1182/blood-2019-127822

Published: 2019

Journal Articles

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

Ryan N Rys, BSc, BA, Maanasa Venkataraman, MSc, Jibin Zeng, MSc, Koren Kathleen Mann, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1520.

https://doi.org/10.1182/blood-2019-130602

Published: 2019

Journal Articles

MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

Kirill A. Lyapichev, MD, L. Jeffrey Medeiros, MD, Shaoying Li, MD, C. Cameron Yin, MD PhD, Guilin Tang, MD, M. James You, MD PhD, Sergej Konoplev, Swaminathan P. Iyer, MD, Carlos E. Bueso-Ramos, MD PhD, Roberto N. Miranda, MD, Jie Xu

Blood (2019) 134 (Supplement_1): 1560.

https://doi.org/10.1182/blood-2019-124556

Published: 2019

Journal Articles

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Patrick R. Hagner, PhD, Michelle Waldman, MS, Falon D. Gray, DVM, DACVP, Renee Yura, PhD, Sarah Hersey, MS, MBA, Henry Chan, PhD, Mingjun Zhang, PhD, Isaac Boss, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 1580.

https://doi.org/10.1182/blood-2019-126115

Published: 2019

Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 1344.

https://doi.org/10.1182/blood-2019-122097

Published: 2019

Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 1585.

https://doi.org/10.1182/blood-2019-123933

Published: 2019

Journal Articles

Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis

Irene Defrancesco, Silvia Zibellini, Emanuela Boveri, Marco Frigeni, Virginia Valeria Ferretti, Ettore Rizzo, Francesca Capuano, Arturo Bonometti, Chiara Candido, Sara Rattotti, Elena Flospergher, Fabio Bergamini, Caterina Zerbi, Marco Paulli, Marzia Varettoni, Luca Arcaini

Blood (2019) 134 (Supplement_1): 1502.

https://doi.org/10.1182/blood-2019-130233

Published: 2019

Journal Articles

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

Blood (2019) 134 (Supplement_1): 1532.

https://doi.org/10.1182/blood-2019-131442

Published: 2019

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim

Blood (2019) 134 (Supplement_1): 1593.

https://doi.org/10.1182/blood-2019-128773

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Retinoic acid–responsive CD8 effector T cells are selectively increased in IL-23–rich tissue in gastrointestinal GVHD

The different flavors and splices of MCL

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Effect of Extended Platelet Storage on Platelet Metabolism and Clot Retraction

Altered Megakaryocytes Are Associated with Development of Pulmonary Fibrosis in Mice Carrying the Hypomorphic Gata1 low Mutation

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes

Euroclonality-NGS DNA Capture Panel for Integrated Analysis of IG/TR Rearrangements, Translocations, Copy Number and Sequence Variation in Lymphoproliferative Disorders

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only